Back to Search
Start Over
Slovenian Memory Clinic Organization with the Introduction of Potential New Alzheimer's Disease Treatment.
- Source :
- Journal of Alzheimer's Disease; 2024, Vol. 99 Issue 2, p471-476, 6p
- Publication Year :
- 2024
-
Abstract
- Slovenia, situated in Central Europe with a population of 2.1 million, has an estimated 44,278 individuals with mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's dementia, rendering them potential candidates for disease-modifying treatment (DMT), such as lecanemab. We identified 114 potential candidates whose real-life expenses for diagnostic process surmount to more than €80,000. Treating all potential candidates nationwide would amount to €1.06 billion, surpassing Slovenia's entire annual medication expenditure for 2022 (€743 million). The introduction of DMTs and the associated logistics, along with potential complications, will significantly change societal, professional, and patient approach to treatment of Alzheimer's disease. [ABSTRACT FROM AUTHOR]
- Subjects :
- ALZHEIMER'S disease
THERAPEUTICS
LECANEMAB
MILD cognitive impairment
Subjects
Details
- Language :
- English
- ISSN :
- 13872877
- Volume :
- 99
- Issue :
- 2
- Database :
- Complementary Index
- Journal :
- Journal of Alzheimer's Disease
- Publication Type :
- Academic Journal
- Accession number :
- 177228807
- Full Text :
- https://doi.org/10.3233/JAD-240190